IRIS (International Remote Imaging Systems) signs letter of intent for sale of unit:
This article was originally published in Clinica
International Remote Imaging Systems (IRIS) has signed a letter of intent with an unnamed international company for the sale of its Perceptive Scientific Instruments subsidiary for between $2.5 million and $5 million. The division makes and markets the PowerGene line of genetic analysers. The Chatsworth, California-based company announced plans to refocus operations on its core urinalysis business and write off assets relating to non-core operations (see Clinica No 885, p 12). IRIS intends to develop lower-cost, faster imaging products.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.